RX Review: Integrating New Topicals Into Scalp Psoriasis Treatment Regimens - Episode 3
In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.
In this HCPLive RX Review Special Report, Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale University, sits down with David Hartigan, a biologic coordinator with Biologic Coordinators of Dermatology, explore the clinical value of a non-steroidal foam formulation in chronic plaque psoriasis management.
In this clip, Shahriari emphasizes that tolerability is a critical determinant of adherence, as patients frequently discontinue treatments that cause burning or stinging, particularly when applied to excoriated or inflamed skin. She identifies simplicity, comfort, and consistency as essential attributes for long-term topical success.
Shahriari explains that patients increasingly seek a once-daily topical that is versatile enough for use across all body areas without risk of skin atrophy or pigment changes. She notes a growing preference in her practice for non-steroidal options like roflumilast, which has become a mainstay alongside topical corticosteroids. The product’s dual availability in cream and foam formulations gives providers and patients greater flexibility, allowing for more personalized care decisions through shared decision-making.
She concludes that the expanded approval of this agent in foam form has significantly advanced the topical PsO landscape. Its hydrating, cosmetically elegant formulation meets both clinical and lifestyle needs, helping patients manage scalp and body psoriasis more effectively and confidently.
Editor's note: The FDA approved Arcutis Biotherapeutics's roflumilast under the name Zoryve as the first foam option available for scalp psoriasis in May 2025.
Part 1: Tackling Real-World Barriers in Scalp Psoriasis Treatment Delivery
Part 2: Formulation Matters: Managing Scalp Psoriasis Across Hair Types
Part 4: Counseling Patients With Psoriasis on Roflumilast and Nonsteroidal Topicals
Part 5: Bridging and Enhancing Biologic Response With Targeted Topicals for Scalp Psoriasis
Part 6: Advocating for Patients: Securing Access to Nonsteroidal Topicals Like Roflumilast
Our Panelists:
Mona Shahriari, MD, is Assistant Clinical Professor of Dermatology at Yale University School of Medicine, the Associate Director of Clinical Trials at CCD Research and a senior editor for the Journal of Psoriasis and Psoriatic arthritis. She also hosts HCPLive's podcast, The Medical Sisterhood.
David Hartigan, is a biologic coordinator for Optima Dermatology and the Education Chair for Biologic Coordinators of Dermatology.
Relevant disclosures for Shahriari include AbbVie, Dermira, Cara, Dermavant, Novartis, Union, BMS, Leo, Eli Lilly, Sanofi, Regeneron, UCB, and others. Hartigan reports no relevant disclosures.
